9938 related articles for article (PubMed ID: 19558193)
21. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
[TBL] [Abstract][Full Text] [Related]
22. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
23. The Cost of Hospice Services in Terminally Ill Patients With Head and Neck Cancer.
Enomoto LM; Schaefer EW; Goldenberg D; Mackley H; Koch WM; Hollenbeak CS
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1066-74. PubMed ID: 26447873
[TBL] [Abstract][Full Text] [Related]
24. Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
Gogebakan KC; Mukherjee K; Berry EG; Sonmez K; Leachman SA; Etzioni R
Cancer; 2021 Aug; 127(16):2926-2933. PubMed ID: 33905529
[TBL] [Abstract][Full Text] [Related]
25. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
26. The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings.
Neuenschwander JF; Silverstein AR; Teigland CL; Kumar S; Zeng EY; Agiro AT; Pottorf WJ; Peacock WF
Adv Ther; 2023 Mar; 40(3):1204-1223. PubMed ID: 36652174
[TBL] [Abstract][Full Text] [Related]
27. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
28. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.
Karve S; Lorenzo M; Liepa AM; Hess LM; Kaye JA; Calingaert B
J Gastric Cancer; 2015 Jun; 15(2):87-104. PubMed ID: 26161282
[TBL] [Abstract][Full Text] [Related]
29. Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma.
Jang S; Poretta T; Bhagnani T; Harshaw Q; Burke M; Rao S
Dermatol Ther (Heidelb); 2020 Oct; 10(5):985-999. PubMed ID: 32548707
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.
Winge-Main A; Robsahm TE; Nyakas M; Festervoll G; Torkilseng E; Thybo S; Pati S; Carroll R
Future Oncol; 2023 Jan; 19(3):205-215. PubMed ID: 36974621
[TBL] [Abstract][Full Text] [Related]
31. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
32. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
33. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
36. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
37. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
38. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
39. The end of life costs for Medicare patients with advanced ovarian cancer.
Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
[TBL] [Abstract][Full Text] [Related]
40. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]